The direct thrombin inhibitors: Their role and use for rational anticoagulation

Eugene P. Frenkel, Yu Min Shen, Barbara B. Haley

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations

Abstract

It is clear that major clinical advantages are achieved when direct thrombin inhibitors are used in venous thromboembolism. These advantages include the inhibition of fibrin-bound thrombin and the inhibition of activation of platelet factor 4. These agents provide more reliable anticoagulant response patterns because they are not significantly bound to plasma proteins and few, if any, drug-drug interactions are seen. The studies to date confirm that not all direct thrombin inhibitors are the same. The new reversible, short-acting catalytic site-specific drugs provide an excellent safety profile and high degree of efficacy for the prophylaxis and treatment of venous thromboembolism and pulmonary embolic states. The availability of the oral prodrug ximelagatran allows reproducible, effective, and safe direct thrombin inhibition without the requirement for coagulation laboratory monitoring; it appears destined to be the oral anticoagulant of the future.

Original languageEnglish (US)
Pages (from-to)119-145
Number of pages27
JournalHematology/Oncology Clinics of North America
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2005

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'The direct thrombin inhibitors: Their role and use for rational anticoagulation'. Together they form a unique fingerprint.

Cite this